[go: up one dir, main page]

PE20070001A1 - Composiciones de tanaproget que contienen etinil estradiol - Google Patents

Composiciones de tanaproget que contienen etinil estradiol

Info

Publication number
PE20070001A1
PE20070001A1 PE2006000630A PE2006000630A PE20070001A1 PE 20070001 A1 PE20070001 A1 PE 20070001A1 PE 2006000630 A PE2006000630 A PE 2006000630A PE 2006000630 A PE2006000630 A PE 2006000630A PE 20070001 A1 PE20070001 A1 PE 20070001A1
Authority
PE
Peru
Prior art keywords
composition
amount
tanaproget
ethinyl estradiol
compositions containing
Prior art date
Application number
PE2006000630A
Other languages
English (en)
Inventor
Arwinder Nagi
Ramarao Chatlapalli
Shamim Hasan
Zafar Ali
Mohamed Ghorab
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37432377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20070001A1 publication Critical patent/PE20070001A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) TANAPROGET QUE SE ENCUENTRA EN UNA CANTIDAD DE 0.1% A 1% P/P DE LA COMPOSICION; B) ETINIL ESTRADIOL QUE SE ENCUENTRA EN UNA CANTIDAD DE 0.03% A 0.05% P/P DE LA COMPOSICION; C) CELULOSA MICROCRISTALINA QUE SE ENCUENTRA EN UNA CANTIDAD DE 30% A 56% P/P DE LA COMPOSICION; D) LACTOSA ANHIDRA QUE SE ENCUENTRA EN UNA CANTIDAD DE 30% A 56% P/P DE LA COMPOSICION; E) CROSCARMELOSA DE SODIO QUE SE ENCUENTRA EN UNA CANTIDAD DE 2% A 6% P/P DE LA COMPOSICION; Y F) ESTEARATO DE MAGNESIO QUE SE ENCUENTRA EN UNA CANTIDAD DE 0.25% A 0.5% P/P DE LA COMPOSICION. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION. DICHA COMPOSICION SE DEGRADA MENOS DE 1% DURANTE UN PERIODO SUPERIOR A UN MES A TEMPERATURA DE 25ºC Y UNA HUMEDAD RELATIVA DE HASTA 60%. EL TANAPROGET ES UN MODULADOR DEL RECEPTOR DE PROGESTERONA SIENDO UTIL PARA LA ANTICONCEPCION, TERAPIA DE REEMPLAZO HORMONAL, ENDOMETRIOSIS
PE2006000630A 2005-06-09 2006-06-07 Composiciones de tanaproget que contienen etinil estradiol PE20070001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68880605P 2005-06-09 2005-06-09

Publications (1)

Publication Number Publication Date
PE20070001A1 true PE20070001A1 (es) 2007-01-29

Family

ID=37432377

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000630A PE20070001A1 (es) 2005-06-09 2006-06-07 Composiciones de tanaproget que contienen etinil estradiol

Country Status (13)

Country Link
US (3) US20060280800A1 (es)
EP (1) EP1893217A2 (es)
JP (1) JP5339903B2 (es)
CN (2) CN103989687A (es)
AR (1) AR057060A1 (es)
AU (1) AU2006258048A1 (es)
BR (1) BRPI0611250A2 (es)
CA (1) CA2610767C (es)
HN (1) HN2006020928A (es)
MX (1) MX2007015571A (es)
PE (1) PE20070001A1 (es)
TW (1) TW200716137A (es)
WO (1) WO2006135638A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100732692B1 (ko) * 1999-05-04 2007-06-27 와이어쓰 프로게스테론 수용체 조절인자인 시클로티오카르바메이트유도체
ES2327783T3 (es) 2005-04-28 2009-11-03 Wyeth Composiciones que contienen tanaproget micronizado.
AR056328A1 (es) * 2005-04-28 2007-10-03 Wyeth Corp TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN
MX2007013469A (es) * 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
PL1877059T3 (pl) * 2005-04-28 2010-07-30 Wyeth Llc Mikroniozowany tanaproget i zawierające go kompozycje
US20060280800A1 (en) 2005-06-09 2006-12-14 Wyeth Tanaproget compositions containing ethinyl estradiol
EA201070715A1 (ru) * 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
EP3763374A1 (en) * 2011-10-17 2021-01-13 Lexicon Pharmaceuticals, Inc. Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20140006315A1 (en) * 2012-07-02 2014-01-02 Stèphane Etheve Method of marketing oregano capsules containing thymoquinone
US9326997B2 (en) 2012-09-24 2016-05-03 Ahlam E. Elakkad Composition and method for treation Oligoovulation, Oligomenorrhea and Amenorrhea
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014159377A1 (en) * 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423699B1 (en) * 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
KR100732692B1 (ko) * 1999-05-04 2007-06-27 와이어쓰 프로게스테론 수용체 조절인자인 시클로티오카르바메이트유도체
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
AR040644A1 (es) 2002-06-25 2005-04-13 Wyeth Corp Un moduladores del receptor de progesterona benzoxazina-2-tiona, una composicion farmaceutica, uso del compuesto para preparar un dedicamento para tratar una enfermedad neoplasica-hormona-dependiente y el uso de un compuesto benzoxazina-2-tiona, benzoxazina-2-ilideno cianamida o benzoxazina-2-iliden
CN1662241A (zh) * 2002-06-25 2005-08-31 惠氏公司 环硫代氨基甲酸酯衍生物在治疗与激素有关的病症中的用途
PE20060378A1 (es) 2004-07-07 2006-06-02 Wyeth Corp Regimenes y kits de progestina ciclica
MX2007001812A (es) * 2004-08-13 2007-03-26 Wyeth Corp Derivados de tanaproget, metabolitos, y usos de los mismos.
PL1877059T3 (pl) 2005-04-28 2010-07-30 Wyeth Llc Mikroniozowany tanaproget i zawierające go kompozycje
MX2007013469A (es) 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
ES2327783T3 (es) 2005-04-28 2009-11-03 Wyeth Composiciones que contienen tanaproget micronizado.
AR056328A1 (es) 2005-04-28 2007-10-03 Wyeth Corp TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN
CN101184738B (zh) 2005-04-28 2012-05-23 惠氏公司 纯化型的tanaproget
US20060280800A1 (en) 2005-06-09 2006-12-14 Wyeth Tanaproget compositions containing ethinyl estradiol

Also Published As

Publication number Publication date
WO2006135638A2 (en) 2006-12-21
MX2007015571A (es) 2008-03-06
JP5339903B2 (ja) 2013-11-13
AR057060A1 (es) 2007-11-14
CA2610767A1 (en) 2006-12-21
HN2006020928A (es) 2011-02-16
AU2006258048A1 (en) 2006-12-21
EP1893217A2 (en) 2008-03-05
US8664208B2 (en) 2014-03-04
CA2610767C (en) 2014-09-23
CN103989687A (zh) 2014-08-20
US20140194398A1 (en) 2014-07-10
BRPI0611250A2 (pt) 2011-02-15
US20120114748A1 (en) 2012-05-10
US20060280800A1 (en) 2006-12-14
CN101193639A (zh) 2008-06-04
JP2008543758A (ja) 2008-12-04
TW200716137A (en) 2007-05-01
WO2006135638A3 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
PE20070001A1 (es) Composiciones de tanaproget que contienen etinil estradiol
PE20070327A1 (es) Composicion que comprende una progestina y un estrogeno
TW200745052A (en) Thyroid hormone receptor agonists
BRPI0713565A2 (pt) composição farmacêutica contendo ácido tetrahidrofólico
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
HN2008000621A (es) Metodo para la anticopcepcion hormonal preventiva bajo demanda
MX338290B (es) Tratamiento de enfermedad de alzheimer, perdida de cognición, perdida de memoria y demencia con precursores de esteroides sexuales en conbinación con moduladores selectivos del receptor de estrógenos.
PE20040157A1 (es) Progestinas no esteroides
BRPI0518553A2 (pt) composiÇço farmacÊutica estÁvel, mÉtodo para estabilizaÇço de pelo menos um ingrediente farmaceuticamente ativo e mÉtodo de uso de celulose microcristalina silicificada
PE20070208A1 (es) Anticoncepcion oral con trimegestona
WO2004000225A3 (en) Use of thio-oxindole derivatives in treatment of hormone-related conditions
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
PE20060853A1 (es) 18-metil-19-nor-17-pregn-4-en-21,17-carbolactonas, asi como preparaciones farmaceuticas que las contienen
MX2009001698A (es) Derivados de oxazolidona como moduladores pr.
PE20070188A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
PE20061243A1 (es) Composicion farmaceutica que comprende derivados de indolil-maleimida
NO20080440L (no) Ikke-steroide progesteronreseptormodulatorer
UY28334A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
DK1159965T3 (da) Anvendelse af en progesteronreceptor-antagonist til forebyggelse eller inhibering af befrugtning
MX2008000070A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona.
TW200734302A (en) Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
MX2023003401A (es) Composicion farmaceutica para prevenir o tratar enfermedad hepatica colestasica, que contiene beta-lapachona como ingrediente activo.
WO2008064217A3 (en) Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol and pharmaceutical formulations thereof

Legal Events

Date Code Title Description
FD Application declared void or lapsed